Medicus Pharma (NASDAQ:MDCX) CEO Dr Raza Bokhari will present at BioFuture 2026 in New York and deliver a keynote at the Global Biotechnology Summit 2026 in Abu Dhabi.
Bokhari will join a BioFuture panel today titled "Beyond the Cure: The Brave New World of Revolutionary Cancer Therapeutics," which will explore next-generation cell therapies, AI-enabled drug discovery and personalized oncology.
He will then deliver the keynote "Precision Medicine: From Capital to Success" at the Abu Dhabi summit on November 12, covering funding precision medicine breakthroughs and scaling personalized healthcare from research to market.
The presentations will highlight CD228V, an early clinical-stage antibody-drug conjugate built on Pfizer's established vedotin linker-payload platform. Medicus is prioritizing clinical proof-of-concept in melanoma, particularly relapsed, refractory or immunotherapy-resistant disease.
They will also feature SkinJect, a localized immuno-oncology product that delivers doxorubicin directly into basal cell carcinoma lesions through a dissolvable microneedle patch. The company is focusing future internally sponsored development on patients with Gorlin syndrome, and the FDA has authorized initiation of SKNJCT-005, a planned registrational Phase 2b study.
Medicus aims to build clinical evidence in defined patient populations while pursuing partnerships.
